Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies

In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights the key data and nursing considerations for integrating BCMA-targeted agents into the treatment plan for R/R MM, with a focus on belantamab mafodotin and idecabtagene vicleucel.
Donna Catamero, ANP-BC, OCN, CCRC
Released: July 19, 2021 Expiration: No longer available for credit

In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University of Texas MD Anderson Cancer Center.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss with patients the available data and rationale for using monoclonal antibodies and antibody–drug conjugates as well as new-generation immunomodulatory agents and proteasome inhibitors for individual patients with MM
  • Provide patient-focused education on the available clinical data and new therapeutic options for the individualized treatment of MM
  • Develop a proactive management plan for adverse events associated with recently approved agents and novel combinations used to treat MM

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Oncopeptides
Sanofi Genzyme Corporation

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Donna Catamero, ANP-BC, OCN, CCRC

Nurse Practitioner
Mount Sinai Hospital
New York, New York

Donna Catamero, APN-BC, OCN, CCRC, has disclosed that she has received fees for non-CME/CE services from GlaxoSmithKline and Oncopeptides and has received consulting fees, has ownership interest in, and has previously received salary from Celgene/Bristol-Myers Squibb.

Staff

Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.
Mark Christiansen, PhD, PA-C
Mark Christiansen, PA-C, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for nurses and physician assistants specializing in hematology/oncology involved in the care of patients with multiple myeloma.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of nurses and other healthcare professionals to optimally care for patients with multiple myeloma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Physician Assistant Continuing Medical Education

Credit Designation

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until July 18, 2022. PAs should only claim commensurate with the extent of their participation.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 19, 2021, through July 18, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Adolfo de la Fuente Burguera, MD
Program Director
Claudio Cerchione, MD, PhD Naval G. Daver, MD person default Pau Montesinos, MD, PhD Eytan M. Stein, MD
Released: December 1, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Claudio Cerchione, MD, PhD
Program Director
Naval G. Daver, MD Adolfo de la Fuente Burguera, MD Courtney DiNardo, MD, MSCE person default Giovanni Martinelli, MD
Released: November 30, 2022

Downloadable PDF resource as a helpful guide for the differences between covalent and emerging non-covalent BTK inhibitors in MCL, from Clinical Care Options (CCO)

Released: November 29, 2022

On-demand webcast from a CAP satellite symposium on the role of pathology in myelodysplastic syndromes, from Clinical Care Options (CCO)

Tal Oren, MD, PhD Alexa J. Siddon, MD Cecilia Yeung, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point ABPath MOC: maximum of 1.0 Lifelong Learning point Released: November 29, 2022 Expired: November 28, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings